

 Pakistan National Accreditation Council	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 166</b>
--	-----------------------------------	---

## **Accreditation No: LAB 166**

**Awarded to**

**Drugs Testing Laboratory, Punjab, Rawalpindi  
Dhamyal Road, Hayal Sharif, Rawalpindi – Pakistan**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **27-12-2018** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **26-12-2024**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

**PAKISTAN NATIONAL ACCREDITATION COUNCIL**

11-03-2022

Date

SD

Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 166</b>
---	-----------------------------------	---

### **Testing Laboratory.**

Accreditation Scope of Drugs Testing Laboratory Punjab Rawalpindi,  
Dhamyal Road, Hayal Sharif, Rawalpindi – Pakistan

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Method
Paracetamol – Active Pharmaceutical Ingredient	Pharmaceutical Testing	Quantitative Analysis/ Identification	Internal Method with reference to British Pharmacopoeia (BP) 2022, ‘Paracetamol Tablets’, Volume#3, Page# 1142-1143
Ibuprofen - Active Pharmaceutical Ingredient	Pharmaceutical Testing	Pharmaceutical Testing	Internal Method with reference to United States Pharmacopoeia (USP) 2021 ‘Ibuprofen Tablets’ (online version)
Paracetamol Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395 / United States Pharmacopoeia (USP) 2021, Chapter# 701/ MS
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417.
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2022, Volume#3, Page# 1142-1143
Ibuprofen Tablets	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2021, (online version)
Ibuprofen Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395 / United States Pharmacopoeia (USP) 2021, Chapter# 701, online version / MS

11-03-2022  
Date

\_\_\_\_\_  
Sd  
Director



**ACCREDITATION  
DOCUMENT**

**F-06/02**  
**Issue Date: 18/08/2020**  
**Rev. No: 09**  
**LAB 166**

	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2021, (online version)
Metformin Tablets	Pharmaceutical Testing	Identification	British Pharmacopoeia (BP) 2022, Volume#3, Page# 969-970
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395 / United States Pharmacopoeia (USP) 2021, Chapter# 701/ MS
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2022, Volume#3, Page# 969-970
Atenolol Tablets	Pharmaceutical Testing	Identification	British Pharmacopoeia (BP) 2022, volume#3, Page# 182 & USP 2021 (online version)
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395/ United States Pharmacopoeia (USP) 2021, Chapter# 701/ MS
Atenolol Tablets	Pharmaceutical Testing	Assay of Active Ingredient	British Pharmacopoeia (BP) 2022, volume#3, Page# 182
	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia USP 2021 (online version)
Ciprofloxacin Tablets	Pharmaceutical Testing	Identification	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395/ United States Pharmacopoeia (USP)

11-03-2022  
Date

Sd  
Director



**ACCREDITATION  
DOCUMENT**

**F-06/02**  
**Issue Date: 18/08/2020**  
**Rev. No: 09**  
**LAB 166**

			2021, Chapter# 701/ MS
	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	Assay of Active Ingredient	British Pharmacopoeia (BP) 2022, Volume#3, page#385-386
Amoxicillin Capsules	Pharmaceutical Testing	Identification	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395/ United States Pharmacopoeia (USP) 2021, Chapter# 701/ MS
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia USP 2021 (online version)
Omeprazole Capsules	Pharmaceutical Testing	Identification	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Ciprofloxacin Injection	Pharmaceutical Testing	Identification	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2021, Chapter#791/MS
	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	Assay of Active Ingredient	British Pharmacopoeia (BP) 2022, Volume#3, Page#385-386
Amoxicillin for oral suspension	Pharmaceutical Testing	Identification	United States Pharmacopoeia USP 2021 (online version)

11-03-2022  
Date

\_\_\_\_\_  
Sd  
Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 166</b>
---	-----------------------------------	---

	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia USP 2021 (online version)
	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2021, Chapter#791, online version /MS
Metronidazole Infusion	Pharmaceutical Testing	Identification	British Pharmacopoeia (BP) 2022, Volume#3, Page#994-995
	Pharmaceutical Testing	Assay of Active Ingredient	British Pharmacopoeia (BP) 2022, Volume#3, Page#994-995
	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2021, Chapter #791, online version /MS
Metronidazole Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022 Appendix XII-A, V-A392-V-A395.
Glibenclamide Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Domperidone Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Diclofenac (film coated) Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Mefenamic acid Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Folic acid, ferrous fumarate Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Meloxicam Tablet	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417

11-03-2022  
Date

Sd  
Director



**ACCREDITATION  
DOCUMENT**

**F-06/02**  
**Issue Date: 18/08/2020**  
**Rev. No: 09**  
**LAB 166**

Cetirizine Tablets	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Moxifloxacin Tablets	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Amlodipine Tablets	Pharmaceutical Testing	Weight Variation	British Pharmacopoeia (BP) 2022 / Consistency of formulated preparation / Appendix XII-C, V-A417
Carvedilol Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Losartan Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Atorvastatin Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Ramipril Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Prednisolone Tablets	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Flurbiprofen Tablet	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Diclofenac (enteric coated) Tablet	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83
Tramadol capsule	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80-83

11-03-2022  
Date

Sd  
Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 18/08/2020</b> <b>Rev. No: 09</b> <b>LAB 166</b>
---	-----------------------------------	---

Chlorpheniramine Tablet	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2022, Volume# 5, Appendix XII-A/Volume #3, Page#80- 83
Ceftriaxone Injection	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2021, Chapter#791, online version /MS
Dexamethasone Sodium Injection	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2021, Chapter#791, online version /MS
Dopamine Injection	Pharmaceutical Testing	pH	British Pharmacopoeia (BP) 2022, Volume#5, Appendix VI, V-A289 - V-A290 /MS
Naloxone Injection	Pharmaceutical Testing	pH	British Pharmacopoeia (BP) 2022, Volume#5, Appendix VI, V-A289 - V-A290 /MS
Atracurium Injection	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2021, Chapter#791, online version /MS
Conductivity for Water for Injection	Pharmaceutical Testing	Conductivity	United States Pharmacopoeia (USP) 2021, Chapter 645, online version.

11-03-2022  
Date

\_\_\_\_\_  
Sd  
Director